NCT05046353SuspendedPhase 1/2
D-serine AudRem: R33 Phase
D-serine Augmentation of Neuroplasticity-based Auditory Learning in Schizophrenia: R33 Phase
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning. D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the D-serine treatment over 16 weeks of a program designed to measure auditory plasticity.
- Status (registry)
- Suspended
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 30 Aug 2021
- Start date
- 1 Dec 2022
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- New York State Psychiatric Institute
- Diseases
- Schizophrenia
- NCT number
- NCT05046353
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in study of investigational medication/device within 4 weeks
- Subjects with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 6 months prior to screening or subjects who represent a significant risk of suicide in the opinion of the investigator
Other illness
- Presence of positive history of unstable significant medical or neurological illness
Lab values
- Pregnant women or women of child-bearing potential, who are either not surgically-sterile or for outpatients, using appropriate methods of birth control. Women of child-bearing potential must have a negative serum beta-hCG pregnancy test at screening.
Other
- Substance abuse (excluding nicotine) within last 60 days
- ECG abnormality that is clinically significant in the context of study participation in the opinion of the study cardiologist
- Current clozapine use. Clozapine is excluded for two reasons: to avoid the potential confound of treatment resistant patients and because of clozapine's intrinsic NMDA agonist
- Positive toxicology screen for any substances of abuse
Who the study is looking for
- Age between 18 and 50
- DSM-V diagnosis of schizophrenia or schizoaffective disorder
- Willing to provide informed consent
- Auditory Cognitive impairment demonstrated by:
- a .MCCB composite domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45) b. And at least one of the following:
- MCCB verbal memory domain score less than or equal to 0.5 standard deviation below normal (T score less than or equal to 45)
- Tone matching score of less than or equal to 77.7%
- Clinically stable for 2 months (CGI less than or equal to 4)
- Moderate or lower cognitive disorganization (PANSS P2 less than or equal to 4)
- Medically stable for study participation
- Willing to use qualified methods of contraception for the study duration and up to 2 months after its end
- Fluent English speaker
- Normal hearing
- Visual acuity corrected to 20/30
- An estimated Glomerular Filtration Rate (GFR) greater than or equal to 60
- Taking an antipsychotic medication other than clozapine at a stable dose for at least 4 weeks
- Judged clinically not to be at significant suicide or violence risk
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYSPI Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.